GSK-356278

DB12542InvestigationalSmall molecule

Gsk356278 has been used in trials studying the treatment and basic science of Anxiety Disorders, Huntington Disease, Depressive Disorder, Huntingtons Disease, and Depressive Disorder, Major, among others.

Chemical structure of GSK-356278
Formula / weight
C21H25N7O2S · 439.54 g/mol (avg)
Code names
GSK356278

Resolves to

Compound
UNII1QTA9P992CCAS720704-34-7PubChem10252640
Structure
InChIKeyAWDJJMXJUOHGLC-UHFFFAOYSA-NSMILESCCN1N=CC2=C(NC3CCOCC3)C(=CN=C12)C1=NN=C(CC2=C(C)N=C(C)S2)O1
Targets
P27815PDE4AQ07343PDE4BQ08499PDE4D

What you can answer from here — as of January 29, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with GSK-356278, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In